Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 8413

1.

Review of guidelines for good practice in decision-analytic modelling in health technology assessment.

Philips Z, Ginnelly L, Sculpher M, Claxton K, Golder S, Riemsma R, Woolacoot N, Glanville J.

Health Technol Assess. 2004 Sep;8(36):iii-iv, ix-xi, 1-158. Review.

2.

Generalisability in economic evaluation studies in healthcare: a review and case studies.

Sculpher MJ, Pang FS, Manca A, Drummond MF, Golder S, Urdahl H, Davies LM, Eastwood A.

Health Technol Assess. 2004 Dec;8(49):iii-iv, 1-192. Review.

3.

A pilot study on the use of decision theory and value of information analysis as part of the NHS Health Technology Assessment programme.

Claxton K, Ginnelly L, Sculpher M, Philips Z, Palmer S.

Health Technol Assess. 2004 Jul;8(31):1-103, iii.

4.

Procedures and methods of benefit assessments for medicines in Germany.

Bekkering GE, Kleijnen J.

Eur J Health Econ. 2008 Nov;9 Suppl 1:5-29. doi: 10.1007/s10198-008-0122-5.

PMID:
18987905
5.

Cost-effectiveness of alternative strategies for the initial medical management of non-ST elevation acute coronary syndrome: systematic review and decision-analytical modelling.

Robinson M, Palmer S, Sculpher M, Philips Z, Ginnelly L, Bowens A, Golder S, Alfakih K, Bakhai A, Packham C, Cooper N, Abrams K, Eastwood A, Pearman A, Flather M, Gray D, Hall A.

Health Technol Assess. 2005 Jul;9(27):iii-iv, ix-xi, 1-158. Review.

6.

Avoiding and identifying errors in health technology assessment models: qualitative study and methodological review.

Chilcott J, Tappenden P, Rawdin A, Johnson M, Kaltenthaler E, Paisley S, Papaioannou D, Shippam A.

Health Technol Assess. 2010 May;14(25):iii-iv, ix-xii, 1-107. doi: 10.3310/hta14250. Review.

8.

Evaluating non-randomised intervention studies.

Deeks JJ, Dinnes J, D'Amico R, Sowden AJ, Sakarovitch C, Song F, Petticrew M, Altman DG; International Stroke Trial Collaborative Group; European Carotid Surgery Trial Collaborative Group.

Health Technol Assess. 2003;7(27):iii-x, 1-173. Review.

9.
10.

[Procedures and methods of benefit assessments for medicines in Germany].

Bekkering GE, Kleijnen J.

Dtsch Med Wochenschr. 2008 Dec;133 Suppl 7:S225-46. doi: 10.1055/s-0028-1100954. Epub 2008 Nov 25. German.

PMID:
19034813
11.

Clinical effectiveness and cost-effectiveness of immediate angioplasty for acute myocardial infarction: systematic review and economic evaluation.

Hartwell D, Colquitt J, Loveman E, Clegg AJ, Brodin H, Waugh N, Royle P, Davidson P, Vale L, MacKenzie L.

Health Technol Assess. 2005 May;9(17):1-99, iii-iv. Review.

12.

Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation.

Shepherd J, Jones J, Frampton GK, Tanajewski L, Turner D, Price A.

Health Technol Assess. 2008 Jun;12(28):iii-iv, ix-95. Review.

13.

A systematic review and economic model of switching from non-glycopeptide to glycopeptide antibiotic prophylaxis for surgery.

Cranny G, Elliott R, Weatherly H, Chambers D, Hawkins N, Myers L, Sculpher M, Eastwood A.

Health Technol Assess. 2008 Jan;12(1):iii-iv, xi-xii, 1-147. Review.

14.

Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling Studies.

Weinstein MC, O'Brien B, Hornberger J, Jackson J, Johannesson M, McCabe C, Luce BR; ISPOR Task Force on Good Research Practices--Modeling Studies.

Value Health. 2003 Jan-Feb;6(1):9-17.

15.

Indirect comparisons of competing interventions.

Glenny AM, Altman DG, Song F, Sakarovitch C, Deeks JJ, D'Amico R, Bradburn M, Eastwood AJ; International Stroke Trial Collaborative Group.

Health Technol Assess. 2005 Jul;9(26):1-134, iii-iv.

16.

Can randomised trials rely on existing electronic data? A feasibility study to explore the value of routine data in health technology assessment.

Williams JG, Cheung WY, Cohen DR, Hutchings HA, Longo MF, Russell IT.

Health Technol Assess. 2003;7(26):iii, v-x, 1-117.

17.

The clinical effectiveness and cost-effectiveness of newer drugs for children with epilepsy. A systematic review.

Connock M, Frew E, Evans BW, Bryan S, Cummins C, Fry-Smith A, Li Wan Po A, Sandercock J.

Health Technol Assess. 2006 Mar;10(7):iii, ix-118. Review.

18.

A preliminary model-based assessment of the cost-utility of a screening programme for early age-related macular degeneration.

Karnon J, Czoski-Murray C, Smith K, Brand C, Chakravarthy U, Davis S, Bansback N, Beverley C, Bird A, Harding S, Chisholm I, Yang YC.

Health Technol Assess. 2008 Jun;12(27):iii-iv, ix-124.

19.

Oral naltrexone as a treatment for relapse prevention in formerly opioid-dependent drug users: a systematic review and economic evaluation.

Adi Y, Juarez-Garcia A, Wang D, Jowett S, Frew E, Day E, Bayliss S, Roberts T, Burls A.

Health Technol Assess. 2007 Feb;11(6):iii-iv, 1-85. Review.

20.

Clinical guidelines and payer policies on fusion for the treatment of chronic low back pain.

Cheng JS, Lee MJ, Massicotte E, Ashman B, Gruenberg M, Pilcher LE, Skelly AC.

Spine (Phila Pa 1976). 2011 Oct 1;36(21 Suppl):S144-63. doi: 10.1097/BRS.0b013e31822ef5b4. Review.

PMID:
21952186

Supplemental Content

Support Center